Autopsy report · NCT02767752

Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Poor accrual and change of SOC (FOLFIRINOX in adjuvant setting)”

The sponsor’s own words in the registry.

Life of this trial

Registered 6 months before it started.
Ran for about 1 year 8 months before it stopped.
21 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Herlev Hospital
Sponsor type: University, hospital or other
Conditions: Pancreatic Cancer
Interventions: T-ChOS; Gemcitabine; Placebo; Capecitabine
Participants: 21
Sites: 1
Countries: Denmark

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.